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Quantitative drug susceptibility testing of Mycobacterium
tuberculosis by use of MGIT 960 and EpiCenter instrumentation
Abstract
Since numbers of drug-resistant Mycobacterium tuberculosis strains are on the rise, the simple
classification into "susceptible" and "resistant" strains based on susceptibility testing at "critical
concentrations" has to be reconsidered. While future studies have to address the correlation of
phenotypic resistance levels and treatment outcomes, a prerequisite for corresponding investigations is
the ability to exactly determine levels of quantitative drug resistance in clinical M. tuberculosis isolates.
Here we have established the conditions for quantitative drug susceptibility testing for first- and
second-line agents using MGIT 960 instrumentation and EpiCenter software equipped with the TB
eXiST module. In-depth comparative analysis of a range of well-characterized susceptible and resistant
clinical isolates has allowed us to propose conditions for testing and to develop criteria for
interpretation.
JOURNAL OF CLINICAL MICROBIOLOGY, June 2009, p. 1773–1780 Vol. 47, No. 6
0095-1137/09/$08.000 doi:10.1128/JCM.02501-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.
Quantitative Drug Susceptibility Testing of Mycobacterium tuberculosis
by Use of MGIT 960 and EpiCenter Instrumentation
Burkhard Springer,1,2,3 Katja Lucke,1,2 Romana Calligaris-Maibach,1,2
Claudia Ritter,1,2 and Erik C. Bo¨ttger1,2*
Institut fu¨r Medizinische Mikrobiologie, Universita¨t Zu¨rich,1 and Nationales Zentrum fu¨r Mykobakterien,2
CH-8006 Zu¨rich, Switzerland, and Institut fu¨r Medizinische Mikrobiologie und Hygiene,
O¨sterreichische Agentur fu¨r Gesundheit und Erna¨hrungssicherheit,
A-8010 Graz, Austria3
Received 30 December 2008/Returned for modification 9 February 2009/Accepted 21 March 2009
Since numbers of drug-resistant Mycobacterium tuberculosis strains are on the rise, the simple classification
into “susceptible” and “resistant” strains based on susceptibility testing at “critical concentrations” has to be
reconsidered. While future studies have to address the correlation of phenotypic resistance levels and treat-
ment outcomes, a prerequisite for corresponding investigations is the ability to exactly determine levels of
quantitative drug resistance in clinical M. tuberculosis isolates. Here we have established the conditions for
quantitative drug susceptibility testing for first- and second-line agents using MGIT 960 instrumentation and
EpiCenter software equipped with the TB eXiST module. In-depth comparative analysis of a range of well-
characterized susceptible and resistant clinical isolates has allowed us to propose conditions for testing and to
develop criteria for interpretation.
Tuberculosis (TB) is a leading cause of morbidity and mor-
tality worldwide. Developing countries are the most vulnera-
ble, with more than 95% of the cases (32, 33). The present
trend is characterized by an alarming emergence of drug re-
sistance (7, 8, 30). Much attention has focused on the burden
of multidrug-resistant (MDR) TB, i.e., resistance to the first-
line drugs isoniazid and rifampin (rifampicin) (32, 33), and the
emergence of extensively drug resistant TB (6, 26). The rise of
drug-resistant TB and the increased susceptibility of the hu-
man population to TB due to coinfection with human immu-
nodeficiency virus are driving the worldwide TB pandemic and
will worsen the situation in the years ahead, with devastating
effects in poor countries, whose economies suffer most from
this development (19, 20).
In the diagnostic laboratory, testing of mycobacteria for drug
susceptibility is substantially different from the general testing
procedures used in bacteriology. Rather than determining
MICs, a single drug concentration, termed the critical concen-
tration, is usually used to categorize a clinical isolate as sus-
ceptible or resistant. This “critical concentration” is more an
epidemiological parameter (to distinguish “wild-type” strains
from “non-wild-type” strains that are able to grow in the pres-
ence of higher drug concentrations [5]) than a clinical cutoff
value established to guide treatment decisions (14). With grow-
ing knowledge about the mechanisms that underlie drug resis-
tance, it has become evident that drug resistance is multifac-
eted and that different mutations may lead to different levels of
resistance. The acquisition of a resistance mutation leading to
a decrease in drug susceptibility should not inevitably exclude
an anti-TB drug from a treatment regimen, since low-level
resistance does not necessarily imply clinical resistance (3).
However, until now, different levels of phenotypic resistance
have only rarely been taken into account in the procedures
used for in vitro drug susceptibility testing (DST) of mycobac-
teria (4).
“Critical concentration”-based DST of primary and second-
ary drugs has been established for the radiometric Bactec 460
instrumentation (Becton Dickinson Microbiology Systems,
Sparks, MD) and is considered the “gold standard” in the
testing of second-line drugs (22, 25). However, the Bactec 460
system has several drawbacks: (i) it involves the use of sharps
and radioisotopes with the need for disposal; (ii) it is only
semiautomated; and (iii) it needs considerable hands-on time.
The nonradiometric MGIT (mycobacterial growth indicator
tube) 960 platform (Becton Dickinsion) has been evaluated
extensively for DST of first-line drugs (1, 2, 15, 29) and has
recently also been evaluated for second-line DST (16, 25). In
contrast to the Bactec 460 instrumentation, the MGIT 960
platform is a fully automated system that uses a fluorescence-
quenching-based oxygen sensor for growth detection.
We have previously characterized quantitative drug resis-
tance levels in clinical strains of drug-susceptible and drug-
resistant Mycobacterium tuberculosis using radiometric Bactec
460 measurements (28). However, for widespread implemen-
tation of quantitative DST in diagnostic mycobacteriology, the
technique chosen should be fully automated, compatible with a
computerized expert system for interpretation (so as to avoid
individual errors and subjectivity), and safe and reliable (e.g., if
possible, the system should not use radioactive material nor
needles, such as syringes, for inoculation nor needles inside the
instrument). To this end, we have subjected a carefully chosen
subset of a previously described and well-characterized collec-
tion of clinical M. tuberculosis isolates (28) to quantitative
measurements of drug susceptibility using the MGIT 960 plat-
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form in conjunction with EpiCenter software equipped with
the TB eXiST module.
MATERIALS AND METHODS
Susceptibility testing using the Bactec 460 system. DST for first- and second-
line anti-TB drugs was performed using the Bactec 460 system as recommended
by the manufacturer (27). A 0.1-ml volume from a positive MGIT tube was
inoculated into Bactec 460 12B vials; the final concentrations of drugs are given
in Table 1. For the drug-free growth control, the bacterial suspension was diluted
1:100 before inoculation (proportion testing). The vials were incubated at 37°C
and read daily until the growth of the control reached a growth index (GI) of
500. Test results were interpreted by comparing the changes in the GI of the
growth control with the flasks containing the test drugs by using the standard
interpretation procedure (if the GI of the drug is greater than or equal to the GI
of the control, the strain is resistant [R]; if the GI of the drug is less than the GI
of the control, the strain is susceptible [S]).
Susceptibility testing using the MGIT 960 system with EpiCenter TB eXiST
software. The MGIT 960 system was used for primary isolation and standard
susceptibility testing of first-line drugs (10) as recommended by the manufac-
turer. MGIT tubes supplemented with 0.8 ml of supplement (MGIT 960 SIRE
supplement; Becton Dickinson) were inoculated with 0.1 ml of the drug solution
and 0.5 ml of the test strain suspension. For preparation of the drug-free growth
control tube, the organism suspension was diluted 1:100 with sterile saline, and
then 0.5 ml was inoculated into the tube (proportion testing). For quantitative
DST using the MGIT 960 instrumentation, we requested Becton Dickinson to
develop custom-designed software with the following characteristics: automated
recording of the readings, additional incubation time beyond the time to posi-
tivity of the drug-free control, minimization of the number of drug-free control
tubes required, graphical representation of the growth unit (GU) value increase
and storage of data, and easy handling and documentation. The software is
EpiCenter, version 5.53, equipped with the TB eXiST module and available from
Becton Dickinson. Table 1 lists the drug concentrations used for comparative
analysis. The susceptibility testing sets were placed in the MGIT 960 instrument
and continuously monitored using EpiCenter (version 5.53) TB eXiST software.
Results were interpreted as follows. At the time when the GU of the drug-free
control tube was 400, if the GU of the drug-containing tube to be compared
was 100, the strain was R. If the GU of the drug-containing tube was 100, it
was incubated for a further 7 days. If it was still100, the strain was S. If the GU
of the drug-containing tube was 100 during this further 7 days of incubation
after the GU of the drug-free control tube reached 400, the strain was
intermediate (I).
Strains and molecular detection of resistance mutations. The isolates inves-
tigated in this analysis represent a subset of 29 clinical M. tuberculosis strains
from a previously reported study (28).
For the identification of resistance mutations, the GenoType MTBDRplus
assay (Hain Lifescience, Nehren, Germany) was used (11, 17). The GenoType
MTBDRplus assay is a reverse hybridization line probe assay designed for rapid
detection of rpoB and katG gene mutations. In addition, the strip harbors two
wild-type probes covering the promoter region of the inhA gene, and four
mutations in this region are targeted using mutated probes (-8T/C, -8T/A,
-15C/T, -16A/G). The assay was performed as recommended by the manufac-
turer. Either the absence of a wild-type probe or a hybridization signal of a
mutant probe is an indication of resistance.
For the detection of mutational alterations associated with resistance to
ethambutol, amikacin, or streptomycin, i.e., embB position 306 (13), 16S rRNA
position 1408 (23), and rpsL positions 42 and 87 (9), PCR-driven gene amplifi-
cation and nucleic acid sequence determination were applied. Amplified gene
fragments were sequenced using the BigDye Terminator cycle-sequencing ready
reaction kit (Applied Biosystems Inc., Foster City, CA) and an ABI 3130 DNA
genetic analyzer (Applied Biosystems).
RESULTS
A representative set of well-characterized clinical M. tuber-
culosis strains, with drug resistance defined at the genotypic
level, was used to establish conditions for quantitative DST on
the basis of the MGIT 960 instrumentation and EpiCenter,
version 5.53, TB eXiST software. A total of 29 clinical isolates
of M. tuberculosis, categorized as resistant to one or more
first-line drugs on the basis of standard critical-concentration
testing, were tested for susceptibility at higher drug concentra-
tions using Bactec 460 and MGIT 960 instrumentation. Table
1 lists the drug concentrations used for comparative analysis.
The EpiCenter software allows continuous monitoring of flu-
orescence, thus enabling a precise assessment of bacterial
growth. Continuous growth monitoring, together with an ex-
tended incubation period of a further 7 days following the
positivity of the drug-free control, facilitated the development
of the term “intermediate growth” as an additional character-
istic in data interpretation. The phenotypic heterogeneity in
isoniazid resistance expression with the katG S315T mutation
has been described previously (28) and may serve to illustrate
the term “intermediate” (Fig. 1).
To determine the accuracy of quantitative DST, we com-
pared the results of MGIT 960 testing with those of radiomet-
ric Bactec 460 testing and related them to the molecular resis-
tance determinants identified. For molecular profiling, the
GenoType MTBDRplus assay (Hain Lifescience, Nehren,
Germany) was used (rifampin, isoniazid, and ethionamide); in
part, mutations were assessed by nucleic acid sequencing
(ethambutol, streptomycin, and amikacin).
For isoniazid, we included 11 strains with low-level drug
resistance (MICs,0.1 mg/liter and1 mg/liter) (Table 2) and
18 strains with resistance levels of 1 mg/liter (Table 3). All
low-level resistant isolates harbored an inhA promoter muta-
tion (C15T). In 14/18 isolates with resistance levels of 1
mg/liter, a katG S315T mutation was present. The results ob-
tained with the MGIT 960 platform correlated well with those
generated by radiometric Bactec 460 testing over the whole
range of drug concentrations tested (Table 3; Fig. 2). The only
major discrepancy (S versus R) was observed at a test concen-
tration of 3 mg/liter. Here the Bactec 460 system consistently
reported susceptibility for a single isolate, while the MGIT 960
system gave a resistant test result; the two systems gave iden-
tical results for this isolate at test concentrations of 1 mg/liter
(resistant) and 10 mg/liter (susceptible).
For rifampin, 11 isolates with resistance levels of1 mg/liter
were included in the analysis. Complete agreement between
the two test systems was observed (Table 3; Fig. 2). Of the 11
isolates tested, 10 showed resistance at50 mg/liter, and all 10
harbored well-described resistance mutations in the rpoB gene
(Table 3). One isolate showed low-level resistance (MIC  1
TABLE 1. Concentrations of drugs used for susceptibility testing
Drug
Concn(s) (mg/liter) used for testing in the
following system:
Bactec 460 MGIT 960
Isoniazid 0.1, 0.4, 1.0, 3.0, 10.0 0.1, 0.4, 1.0, 3.0, 10.0
Rifampin 1.0, 3.0, 10.0, 50.0 1.0, 3.0, 10.0, 50.0
Ethambutol 2.5, 5.0, 12.5, 50.0 2.5, 5.0, 12.5, 25.0, 50.0
Streptomycin 1.0, 10.0, 50.0b 1.0, 4.0, 20.0b
Amikacin 1.0, 10.0, 50.0 1.0, 4.0, 20.0
Ethionamide 2.5, 12.5a 2.5, 12.5a
Ofloxacin 2.0, 10.0, 20.0 2.0, 10.0, 50.0
Linezolid 0.4, 4.0 1.0, 4.0
Capreomycin 5.0 1.25, 5.0, 25.0
a Additional testing for selected strains at concentrations of 1.25, 2.5, 5.0, 12.5,
and 25.0 mg/liter.
b Additional data points were determined for selected strains.
1774 SPRINGER ET AL. J. CLIN. MICROBIOL.
 at Universitaet Zuerich on O
ctober 5, 2009 
jcm.asm.org
D
ow
nloaded from
 
mg/liter and  3 mg/liter) with no detectable rpoB alteration;
intermediate test results were not observed.
Ethambutol test results correlated well between the Bactec
460 and MGIT 960 (Table 3; Fig. 2), with three intermediate
test results each obtained with the MGIT 960 at 5 mg/liter and
at 12.5 mg/liter. Comparison of the test concentration of 25
mg/liter (MGIT 960) with that of 50 mg/liter (Bactec 460)
pointed to one discrepancy: the Bactec 460 system reported a
sensitive result, while in MGIT 960 testing, the isolate showed
resistance at a concentration of 25 mg/liter. Testing of the
FIG. 1. Phenotypic heterogeneity in the isoniazid resistance of isolates with the katG S315 mutation and the term “intermediate” in MGIT 960
testing with EpiCenter (version 5.53) TB eXiST software. (A) Isolate 177836, resistant at 0.1, 1.0, 3.0, and 10.0 mg/liter; (B) isolate 186137, resistant
at 0.1, 1.0, and 3.0 mg/liter and intermediate at 10.0 mg/liter; (C) isolate 186069, resistant at 0.1, 1.0, and 3.0 mg/liter and susceptible at 10.0 mg/liter;
(D) isolate 176291, resistant at 0.1 and 1.0 mg/liter, intermediate at 3.0 mg/liter, and susceptible at 10.0 mg/liter. Drug concentrations are
represented by colors as follows: blue, 0.1 mg/liter; green, 1.0 mg/liter, yellow, 3.0 mg/liter, red, 10.0 mg/liter; black, drug-free growth control.
TABLE 2. Clinical strains with low-level isoniazid resistance
Strain Method
Susceptibility to the following drug at the indicated concn (mg/liter):
Genetic resistanceIsoniazid Ethionamide
0.1 0.4 1.0 3.0 10.0 1.25 2.5 5.0 12.5 25.0
TBC 2694 Bactec 460 R S S S S R R NDa S S katG, wtb; inhA,
C15T
MGIT 960 R I I S S R R R I S
TBC 4269 Bactec 460 R S S S S R R R R R katG, wt; inhA, C15T
MGIT 960 R I I S S R R R R R
NZM 117 Bactec 460 R S S S S R R ND S S katG, wt; inhA, C15T
MGIT 960 R I S S S R R R S S
NZM 150 Bactec 460 R S S S S R R R R ND katG, wt; inhA, C15T
MGIT 960 R I S S S R R R R I
NZM 188 Bactec 460 R S S S S R R ND S S katG, wt; inhA, C15T
MGIT 960 R I S S S R R R S S
TBC 2339 Bactec 460 R S S S S R R ND S S katG, wt; inhA, C15T
MGIT 960 R S S S S R R R R I
TBC 179320 Bactec 460 R S S S S R R R R ND katG, wt; inhA, C15T
MGIT 960 R I S S S R R R R R
TBC 179987 Bactec 460 R S S S S R R ND S S katG, wt; inhA, C15T
MGIT 960 R S S S S R R R S S
NZM 186008 Bactec 460 R S S S S R R ND S S katG, wt; inhA, C15T
MGIT 960 R S S S S R R R S S
NZM 186016 Bactec 460 R S S S S R R ND S S katG, wt; inhA, C15T
MGIT 960 R I S S S R R R S S
TBC 176592 Bactec 460 R S S S S R S ND S S katG, wt; inhA, C15T
MGIT 960 R I S S S R R R S S
a ND, not done.
b wt, wild type.
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isolate at a concentration of 50 mg/liter in MGIT 960 gave a
susceptible test result, indicating a MIC for the isolate between
25 and 50 mg/liter. Seven of the 12 isolates with resistance
levels of 2.5 mg/liter showed mutations in embB codon 306,
while 5 isolates showed a wild-type (ATG) codon. No resis-
tance of 50 mg/liter was found.
Ten isolates with streptomycin resistance levels of 1 mg/
liter were included in our study. Resistance at 1 mg/liter was
consistently detected with both systems (Table 3; Fig. 2). All
isolates (n  4) with resistance levels of 50 mg/liter (Bactec
460) or 20 mg/liter (MGIT 960) harbored an AAG3AGG
mutation at codon 42 of the rpsL gene. Of the strains with
lower resistance levels (n  6), two harbored AAG3AGG
mutations at codon 87 of the rpsL gene; in four strains with a
low-level-resistant phenotype (4 mg/liter), no rpsL mutation
was found.
To further evaluate the capacity of the MGIT 960 system for
quantitative DST of second-line agents, we determined the
resistance profiles of M. tuberculosis isolates for ethionamide,
amikacin, ofloxacin, capreomycin, and linezolid.
Nineteen isolates showed ethionamide resistance of 2.5
mg/liter in at least one of the two test systems. Of the 19
isolates tested, 2 strains showed deviations at a test concentra-
tion of 2.5 mg/liter (Tables 2 and 4): the Bactec 460 system
gave a susceptible test result, while resistance was found using
the MGIT 960 system. The two strains consistently showed a
resistant phenotype at a test concentration of 1.25 mg/liter and
susceptibility at a test concentration of 12.5 mg/liter for both
test systems. At high drug concentrations, the MGIT 960 sys-
tem tended to yield more resistant results than the Bactec 460
system, leading to four discrepancies at a test concentration of
12.5 mg/liter (Fig. 2).
FIG. 2. Correlation of Bactec 460 and MGIT 960 susceptibility testing results.
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Of 12 strains tested, one isolate showed high-level resistance
to amikacin (50 mg/liter). This isolate harbored the typical
16S rRNA mutation A1408G (23). Resistance at all test con-
centrations for this isolate, as well as susceptibility for the other
strains investigated, was consistently determined with both test
systems (Table 4).
Twelve strains were available for the comparison of testing
for susceptibility to ofloxacin. Both systems consistently gave
susceptible test results at a concentration of 2 mg/liter for 11
isolates. One isolate showed resistance at 2 mg/liter and sen-
sitivity at 10 mg/liter (Table 4).
For linezolid and capreomycin, no resistant isolates with
MICs above 4 mg/liter and 5 mg/liter, respectively, were
present in the collection of strains under investigation. For the
isolates studied, both systems consistently revealed sensitive
test results at these drug concentrations (Table 4).
DISCUSSION
With the global rise of MDR strains, there is an increasing
need to determine susceptibility to first and second-line anti-
TB agents exactly. Treatment of patients with drug-resistant
TB should be based on reliable and quantitative measures of
susceptibility testing, a cornerstone for preventing further am-
plification of resistance (18) and for optimally exploiting avail-
able compounds. Detailed knowledge on quantitative drug re-
sistance may guide empirical treatment of drug-resistant TB,
e.g., addressing whether and when to add second-line drugs. A
fundamental drawback to this strategy is that even in industri-
alized countries, only a limited panel of anti-TB drug concen-
trations is tested, leaving the exact resistance level of clinical
M. tuberculosis isolates vestigial. In principle, automatic sys-
tems have the potential to meet the challenge of precise de-
terminations of drug resistance levels with reasonable labor
input. The MGIT 960 platform has been extensively validated
for testing susceptibility to first-line anti-TB agents at critical
drug concentrations (2, 24).
Here we systematically evaluated the performance of the
MGIT 960 instrumentation for quantitative susceptibility test-
ing of drug-resistant clinical isolates of M. tuberculosis. To
investigate the underlying molecular resistance mechanisms,
we used direct PCR-mediated sequence analysis of nucleic
acids or the GenoType MTBDRplus assay. Resistance to iso-
niazid or ethionamide is due mainly to alterations in proteins
that metabolize the prodrug into its active component, such as
KatG or EthA. In contrast, resistance to rifampin, ethambutol,
TABLE 4. Clinical M. tuberculosis strains with drug resistance: second line drugs
Strain Method
Ethionamide Amikacin Susceptibility to the following drug at the indicatedconcn (mg/liter):
Susceptibility at the
following concn
(mg/liter):
Genetic
resistance
Susceptibility at the
following concn
(mg/liter):
Genetic
resistance
Ofloxacin Linezolid Capreomycin
1.25 2.5 5 12.5 25 1 4 10 20 50 2 10 20 50 0.4 1 4 1.25 5 25
NZM 130 Bactec 460 R R NDa S S inhA, wtb S ND S ND S ND S S S ND S ND S ND ND ND
MGIT 960 R R R R S S S ND S ND S S ND S ND S S I S S
NZM 179 Bactec 460 R R R R ND inhA, C15T S ND S ND S ND S S S ND S ND S ND S ND
MGIT 960 R R R R I S S ND S ND S S ND S ND S S I S S
NZM 186006
(NZM 154/04)
Bactec 460 ND ND ND ND ND inhA, wt S ND S ND S ND S S S ND R ND S ND S ND
MGIT 960 ND ND ND ND ND S S ND S ND S S ND S ND S S I S S
NZM 186137
(NZM 152/04)
Bactec 460 R R ND S ND inhA, wt R ND R ND R rrn, A1408G S S S ND R ND S ND S ND
MGIT 960 R R R R R R R ND R ND S S ND S ND S S R ND S
TBC 6893 Bactec 460 S S S S S inhA, wt S ND S ND S ND S S S ND S ND S ND ND ND
MGIT 960 ND S S S S S S ND S ND S S ND S ND S S R S S
TBC 3106 Bactec 460 S S ND S S inhA, wt S ND S ND S ND S S S ND S ND S ND S ND
MGIT 960 ND S ND S S S S ND S ND S S ND S ND S S S S S
NZM 186038
(NZM 3/05)
Bactec 460 R R ND S S inhA, wt S ND S ND S ND S S S ND R ND S ND S ND
MGIT 960 R R R I S S S ND S ND S S ND S ND S S S S S
TBC 176291 Bactec 460 ND ND ND ND ND inhA, wt S ND S ND S ND S S S ND ND ND ND ND ND ND
MGIT 960 ND ND ND ND ND S S ND S ND S S ND S ND S S S S S
TBC 177836 Bactec 460 R R ND S S inhA: wt S ND S ND S ND S S S ND S ND S ND S ND
MGIT 960 R R R R R S S ND S ND S S ND S ND S S S S S
TBC 181783 Bactec 460 R R R R ND inhA: C15T S ND S ND S ND R S S ND R ND S ND S ND
MGIT 960 R R R R R S S ND S ND R S ND S ND S S S S S
NZM 186069 Bactec 460 ND ND ND ND ND inhA: wt S ND S ND S S S S ND R ND S ND S ND
MGIT 960 ND ND ND ND ND S S ND S ND S S ND S ND S S R S S
TBC 6890 Bactec 460 S S S S S inhA: wt ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
MGIT 960 ND S S S S ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
TBC 7392 Bactec 460 ND ND ND ND ND inhA: wt ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
MGIT 960 ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
TBC 295 Bactec 460 R R R R ND inhA: wt S ND S ND S ND S S S S S ND S ND ND ND
MGIT 960 R R R R R S S ND S ND S S S S ND S S S S S
TBC 179882 Bactec 460 ND ND ND ND ND inhA: wt ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
MGIT 960 ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
NZM 186073 Bactec 460 S S S S ND inhA: wt ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
MGIT 960 S S S S ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
NZM 186044 Bactec 460 R S S S ND inhA: C15T ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
MGIT 960 R R R S S ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
NZM 178364 Bactec 460 ND ND ND ND ND inhA: wt ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
MGIT 960 ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
a ND, not done.
b wt, wild type.
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streptomycin, or quinolones is due to mutational alterations in
genes encoding the drug target itself, such as rpoB, rpsL, rrs, or
gyrA (21, 31).
For the first-line drugs, the quantitative resistance levels
determined by the Bactec 460 and MGIT 960 systems were in
good agreement. Introduction of the parameter “intermedi-
ate,” however, allowed a more-precise determination of resis-
tance in the MGIT 960 system. It turned out that susceptibility
testing of isolates with MICs near the test concentration may
result in intermediate test results in the MGIT 960 system. The
most prominent isoniazid resistance-conferring katG mutation
(S315T) is associated with a heterogeneous resistance pheno-
type, with MICs ranging between 1 and 10 mg/liter.
The need for international standardization of testing of sus-
ceptibility to second-line anti-TB agents still remains. We have
evaluated the performance of the MGIT 960 system for quan-
titative testing of susceptibility to the second-line drugs ethion-
amide, amikacin, ofloxacin, linezolid, and capreomycin. The
results with the two test systems show good concordance. How-
ever, the conclusions are limited due to the small number of
resistant isolates available to us. The drug most frequently
affected by Bactec 460–MGIT 960 discrepancies was ethion-
amide. This is in accordance with previous studies (12, 25),
which revealed more resistant results with the MGIT 960 in-
strumentation than with comparative test systems. Promoter
alterations of inhA resulting in ethionamide resistance were
observed in 14 of our ethionamide-resistant isolates (Tables 2
and 4). However, ethionamide resistance may also be due to
ethA mutations not included in the GenoType MTBDRplus
assay.
In general, the MGIT 960 system tended to give resistant test
results more frequently than the Bactec 460 system. Medium
differences and technical differences in the procedure used for
growth measurement may account for this finding. Both instru-
ments determine growth as a measure of metabolic activity. The
Bactec 460 instrument measures volatile radioactive CO2 as me-
tabolized from the radioactive precursor palmitic acid; for this
purpose, most of the gaseous phase in the vial is removed and
replaced. In contrast, the MGIT 960 instrument uses a fluores-
cence-quenching-based oxygen sensor for growth detection with-
out manipulation of the closed vial. Under conditions of exceed-
ingly slow growth, e.g., near the MIC, the Bactec 460 system
would be expected to result in “false” susceptible test results,
since it constantly depletes the vial of the little CO2 produced.
TABLE 5. Recommendations for quantitative DST on the basis of the EpiCenter-equipped MGIT 960 system
Drug Recommendation Comment
Isoniazid 0.1 mg/liter is used for screening Mutations in inhA typically lead to R at 0.1 mg/
liter and S at 1.0 mg/liter; mutations in katG
result in R at 1.0 mg/liter and show varying test
results at 10.0 mg/liter
Low-level-resistant isolates are R at 0.1 mg/liter and S at 1.0 mg/liter
R at 10.0 mg/liter indicates that isoniazid is of no clinical use
Test results of R at 1.0 mg/liter and S at 10.0 mg/liter need further clinical
data for interpretation
1.0 mg/liter is presumably the most important concn to test
Rifampin 1.0 mg/liter is used for screening Most, if not all, mutations in rpoB are associated
with R at 50.0 mg/liter; good correlation
between genotype and phenotype
10.0 mg/liter is used to recognize high-level drug resistance
Ethambutol 5.0 mg/liter is used for screening Isolates with mutations in embB are mostly, if not
always, susceptible or intermediate at 25.0 mg/
liter
25.0 mg/liter is used to recognize high-level drug resistance
Streptomycin 1.0 mg/liter is used for screening Good correlation between genotype and phenotype
20.0 mg/liter is used to recognize high-level drug resistance
4.0 mg/liter is used to separate low-level (R at 1.0 mg/liter; S at 4.0 mg/
liter) from intermediate (R at 1.0 mg/liter; I or R at 4.0 mg/liter; S at
20.0 mg/liter) resistance
Amikacin 1.0 mg/liter is used for screening
20.0 mg/liter is used to recognize high-level drug resistance
4.0 mg/liter is used to separate low-level (R at 1.0 mg/liter; S at 4.0 mg/
liter) from intermediate (R at 1.0 mg/liter; I or R at 4.0 mg/liter; S at
20.0 mg/liter) resistance
Ethionamide 2.5 mg/liter is used for screening Mutations in inhA (C15T) may show phenotypic
variability: unanimously R at 2.5 and 5.0 mg/
liter; I or R at 12.5 mg/liter; S, I, or R at 25.0
mg/liter
Additional testing at 12.5 mg/liter
Ofloxacin 2.0 mg/liter is used for screening
Additional testing at 10.0 and 50.0 mg/liter
Capreomycin 5.0 mg/liter is used for screening
Additional testing at 25.0 mg/liter
Linezolid 1.0 mg/liter is used for screening
Additional testing at 4.0 mg/liter
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Existing procedures for DST of mycobacteria are adequate
for screening but require complementation with quantitative
DST measures, in particular for those drugs where heteroge-
neity in phenotypic resistance is present. We have established
the conditions for quantitative DST using the MGIT 960 sys-
tem in combination with EpiCenter software equipped with the
TBeXiST module, thus providing a fully automated walk-away
system for quantitative DST of M. tuberculosis. This platform
allows electronic data management and is compatible with
expert systems for interpretation. The MGIT 960 platform in
conjunction with the EpiCenter software shows high consis-
tency with Bactec 460 test results over a wide range of con-
centrations tested for first- and second-line anti-TB drugs.
While we note that further studies are needed to address the
correlation of phenotypic resistance levels and treatment out-
come, we have summarized our recommendations for quanti-
tative DST of M. tuberculosis in Table 5. Widespread imple-
mentation of MGIT 960 protocols for quantitative DST should
provide standardized data to enable the correlation of results
from quantitative DST with clinical outcomes by high-through-
put statistical analysis in order to address the issue of pheno-
typic drug resistance levels and treatment failure. In addition,
data sets obtained by an automated standardized procedure
based on agreed guidelines provide optimal input for monitor-
ing the epidemiology of resistance at a supranational level.
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